Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

acute kidney injury

- PMLiVE

Evotec and Vifor announce joint venture for kidney disease treatments

Both companies will split the clinical and commercial costs equally

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

Heart research campaign urges chocolate detox for workers

British Heart Foundation hopes to inspire officer workers to abstain in March

AstraZeneca AZ

AZ, FibroGen’s anaemia drug on course for first filing this year

Potential first-in-class blockbuster lines up to seek approval in China

- PMLiVE

Amgen wins European approval for Parsabiv

Follows FDA knock-back in August for the chronic kidney disease treatment

- PMLiVE

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

AstraZeneca AZ

AZ looks beyond diabetes with Forxiga trials

Will investigate dapagliflozin in kidney disease and heart failure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links